An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …

CDK4/6 inhibition substantially improves progression-free survival (PFS) for women with
advanced estrogen receptor-positive breast cancer, although there are no predictive …

Various recent studies have focused on analyzing tumor genetic material released into the
blood stream, known as circulating tumor DNA (ctDNA). Herein, we describe current …

The term liquid biopsy (LB) refers to the use of various biological fluids as a surrogate for
neoplastic tissue to achieve information for diagnostic, prognostic and predictive purposes …

Context: Immune checkpoint blockade is associated with endocrine-related adverse events.
Thyroid dysfunction during pembrolizumab therapy, an anti-programmed cell death 1 (PD-1) …

New sensitive assays are currently available for the detection of circulating tumor DNA
(ctDNA) and circulating tumor cells (CTC). However, there remains a need for …

Recently, many genome‐wide profiling studies provided insights into the molecular make‐
up of major cancer types. The deeper understanding of these genetic alterations and their …

Summary Background Patients with BRAF V600-mutant melanoma benefit from treatment
with the combination of BRAF and MEK inhibitors, but resistance and disease progression …

Background Melanoma lacks validated blood-based biomarkers for monitoring and
predicting treatment efficacy. Cell-free circulating tumour DNA (ctDNA) is a promising …